Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Antimicrobial Agents and Chemotherapy
Eleftheria MavridouPaul E Verweij

Abstract

The in vivo efficacy of posaconazole against 4 clinical Aspergillus fumigatus isolates with posaconazole MICs ranging from 0.03 to 16 mg/liter, as determined by CLSI method M38A, was assessed in a nonneutropenic murine model of disseminated aspergillosis. The underlying resistance mechanisms of the isolates included substitutions in the cyp51A gene at codon 220 (M220I), codon 54 (G54W), and codon 98 (L98H). The latter was combined with a 34-bp tandem repeat in the gene promoter region (TR L98H). The control isolate exhibited a wild-type phenotype without any known resistance mechanism. Oral posaconazole therapy was started 24 h after infection and was given once daily for 14 consecutive days. Mice were treated with four different doses (1 to 64 mg/kg of body weight), and survival was used as the end point. Survival was dependent both on the dose and on the MIC. The Hill equation with a variable slope fitted the relationship between the dose/MIC ratio and 14-day survival well (R2, 0.92), with a 50% effective dose (ED50) of 29.0 mg/kg (95% confidence interval [CI], 15.6 to 53.6 mg/kg). This also applied to the relationship between the area under the plasma concentration-time curve (AUC)/MIC ratio and 14-day survival (50% effectiv...Continue Reading

References

Nov 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·V T Andriole
Jun 1, 1997·Antimicrobial Agents and Chemotherapy·D W DenningS L Kelly
Apr 9, 1999·Clinical Microbiology Reviews·J P Latgé
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·E DannaouiF Persat
Dec 27, 2002·The New England Journal of Medicine·Adilia WarrisPaul E Verweij
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Adriana M NascimentoDavid S Perlin
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·D AndesDavid Loebenberg
Jan 28, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Anima GhosalShmuel Zbaida
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·Philip KrieterRachel Courtney
Apr 6, 2007·The New England Journal of Medicine·Paul E VerweijWillem J G Melchers
Jul 10, 2007·Lancet·Coretta van Leer-ButerPaul E Verweij
Jul 23, 2008·Antimicrobial Agents and Chemotherapy·Maiken Cavling ArendrupCornelia Lass-Flörl
Sep 17, 2008·Antimicrobial Agents and Chemotherapy·Paul E VerweijJohan W Mouton
Nov 19, 2008·Antimicrobial Agents and Chemotherapy·Roger J M BrüggemannDavid M Burger
Mar 11, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jan W M van der LindenPaul E Verweij
Jul 25, 2009·Emerging Infectious Diseases·Susan J HowardDavid W Denning

❮ Previous
Next ❯

Citations

Nov 7, 2012·The Journal of Antimicrobial Chemotherapy·Seyedmojtaba SeyedmousaviJohan W Mouton
Mar 7, 2013·The Journal of Antimicrobial Chemotherapy·Yanan ZhaoMaiken C Arendrup
Nov 28, 2012·Antimicrobial Agents and Chemotherapy·Seyedmojtaba SeyedmousaviPaul E Verweij
Mar 7, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Jul 31, 2012·Eukaryotic Cell·Sanjoy PaulW Scott Moye-Rowley
Jun 8, 2012·Journal of Clinical Microbiology·Simone M T CampsPaul E Verweij
Jan 29, 2010·Journal of Clinical Microbiology·Jan W M van der LindenPaul E Verweij
Oct 18, 2011·Emerging Infectious Diseases·Jan W M van der LindenPaul E Verweij
Jan 1, 2014·The Journal of Antimicrobial Chemotherapy·H Ruth AshbeeWilliam W Hope
Jul 30, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Seyedmojtaba SeyedmousaviPaul E Verweij
Sep 24, 2013·Expert Review of Anti-infective Therapy·Seyedmojtaba SeyedmousaviRoger J M Brüggemann
Apr 29, 2015·Expert Review of Clinical Pharmacology·Jason N MooreWalter K Kraft
Sep 12, 2015·International Journal of Antimicrobial Agents·A ForastieroA Gomez-Lopez
Jan 1, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C Lass-Flörl
Aug 18, 2012·Diagnostic Microbiology and Infectious Disease·S Krishnan NatesanP H Chandrasekar
Aug 4, 2012·Diagnostic Microbiology and Infectious Disease·Enrique CalvoJosep Guarro
Mar 13, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maiken C ArendrupWilliam W Hope
May 1, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M C ArendrupUNKNOWN European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
Sep 25, 2016·Revista iberoamericana de micología·Diego H CáceresTonny W Naranjo
Mar 15, 2018·Medical Mycology·Agustin Resendiz SharpeUNKNOWN ISHAM/ECMM Aspergillus Resistance Surveillance working group
Mar 28, 2018·Antimicrobial Agents and Chemotherapy·Fekade B SimeJason A Roberts
May 23, 2015·Future Microbiology·Michelle R Ananda-Rajah, Dimitrios Kontoyiannis
Oct 28, 2015·Antimicrobial Agents and Chemotherapy·Adela Martin-VicenteJosep Guarro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Paul E VerweijDavid W Denning
The New England Journal of Medicine
Paul E VerweijWillem J G Melchers
© 2022 Meta ULC. All rights reserved